Evidence map›Paper›PMID 42094229›Full record

ArticleERJ open research2026

Serotype distribution and coverage by pneumococcal vaccines in hospitalised adults with pneumococcal pneumonia in Germany.

Dian Karssen, Lisa M Hessels, Grit Barten-Neiner, Wolfgang Bauer, Sandra Franch-Arroyo, Thomas Fühner, Christina O Hassiepen, David F Heigener, Sebastiaan Hullegie, Rianne Jahja and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Dian KarssenJulius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht University, Utrecht, The Netherlands.
Lisa M HesselsJulius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht University, Utrecht, The Netherlands.
Grit Barten-NeinerCAPNETZ STIFTUNG, Hannover, Germany.
Wolfgang BauerCharité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
Sandra Franch-ArroyoEuropean Clinical Research Alliance on Infectious Diseases (ECRAID), Utrecht, The Netherlands.
Thomas FühnerKRH Klinikum Siloah, Hannover, Germany.
Christina O HassiepenEuropean Clinical Research Alliance on Infectious Diseases (ECRAID), Utrecht, The Netherlands.
David F HeigenerAgaplesion Diakonieklinikum Rotenburg, Rotenburg, Germany.
Sebastiaan HullegieEuropean Clinical Research Alliance on Infectious Diseases (ECRAID), Utrecht, The Netherlands.
Rianne JahjaEuropean Clinical Research Alliance on Infectious Diseases (ECRAID), Utrecht, The Netherlands.
Kelly D JohnsonMerck & Co., Inc., Rahway, NJ, USA.ORCID https://orcid.org/0000-0002-4275-6135
Julius KremlingKlinikum Dortmund, Dortmund, Germany.
Mathias W PletzInstitute of Infectious Diseases and Infection Control, Jena University Hospital/Friedrich Schiller University Jena, Jena, Germany.ORCID https://orcid.org/0000-0001-8157-2753
Craig S RobertsMerck & Co., Inc., Rahway, NJ, USA.
Gernot G U RohdeUniversitatsklinikum Frankfurt, Goethe University Frankfurt, Frankfurt, Germany.ORCID https://orcid.org/0000-0002-5193-7755
Madelyn RuggieriMerck & Co., Inc., Rahway, NJ, USA.
Jochen SchneiderKlinikum Rechts der Isar, Technischen Universität München, Munich, Germany.
Daiana StolzUniversity Hospital Freiburg, Freiburg, Germany.ORCID https://orcid.org/0000-0003-0099-882X
Todd D SwarthoutJulius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht University, Utrecht, The Netherlands.
Thomas WeissMerck & Co., Inc., Rahway, NJ, USA.
Cornelis H Van WerkhovenJulius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID https://orcid.org/0000-0002-0626-4635
Martin WitzenrathDepartment of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Campus Mitte, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0002-9787-5633
Marc J M BontenJulius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht University, Utrecht, The Netherlands.
Cristina Prat AymerichJulius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID https://orcid.org/0000-0001-6974-9165

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Understanding the prevalence of pneumococcal serotypes in hospitalised patients with community-acquired pneumonia (CAP) is critical for vaccine development and implementation of future public health policies. Pneumococcal conjugate vaccines (PCVs) have been implemented to decrease the burden of pneumococcal disease. This study aims to identify the serotype distribution of pneumococcal CAP in Germany. Methods: This interim analysis of a multicentre, prospective, active observational study includes patients aged ≥18 years hospitalised with CAP in seven German hospitals. Patients were enrolled between August 2022 and September 2024. To determine CAP aetiology, microbiological tests were performed according to local standard of care. Urinary antigen testing for Results: Conclusion: Among adults hospitalised with CAP in Germany,

Identifiers

PMID42094229
PMCPMC13139923

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.